BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report January – June 2019

Thu, Jul 11, 2019 08:00 CET

BioArctic: Significant progress in the projects and additional milestone paymentSummary of key events for the second quarter 2019 · BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease · Alzheimer’s Clinical Trials Consortium and Eisai announced that BAN2401 will be evaluated in a clinical study for prevention of Alzheimer’s disease · Ewa Björling was elected new member of the board at the Annual General Meeting · The Annual General Meeting approved the introduction of an employee warrant program

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report January – June 2019

Subscribe

Media

Share

About Us

Interim Report January – June 2019

Subscribe

Media